State Street’s X4 Pharmaceuticals XFOR Stock Holding History

State Street’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.67M	Buy	403,534 +205,300	+104%	+$769K	﹤0.01%	3349
2025 Q4	$793K	Buy	198,234 +159,500	+412%	+$579K	﹤0.01%	3575
2025 Q3	$132K	Buy	38,734 +23,200	+149%	+$59.8K	﹤0.01%	4000
2025 Q2	$29.5K	Sell	15,534 -86,302	-85%	-$353K	﹤0.01%	4164
2025 Q1	$722K	Sell	101,836 -74	-0.1%	-$1.02K	﹤0.01%	3509
2024 Q4	$2.24M	Buy	101,910 +3,480	+4%	+$55.5K	﹤0.01%	3284
2024 Q3	$1.98M	Buy	98,430 +6,304	+7%	+$132K	﹤0.01%	3334
2024 Q2	$1.6M	Buy	92,126 +8,007	+10%	+$262K	﹤0.01%	3387
2024 Q1	$3.51M	Buy	84,119 +3,193	+4%	+$88.8K	﹤0.01%	3073
2023 Q4	$2.04M	Buy	80,926 +1,638	+2%	+$39.8K	﹤0.01%	3306
2023 Q3	$2.59M	Buy	79,288 +5,302	+7%	+$231K	﹤0.01%	3219
2023 Q2	$4.31M	Buy	73,986 +68,298	+1,201%	+$3.51M	﹤0.01%	3068
2023 Q1	$148K	Hold	5,688	–	–	﹤0.01%	4171
2022 Q4	$169K	Buy	5,688 +3,864	+212%	+$183K	﹤0.01%	4169
2022 Q3	$94K	Hold	1,824	–	–	﹤0.01%	4482
2022 Q2	$53K	Hold	1,824	–	–	﹤0.01%	4712
2022 Q1	$96K	Buy	1,824 +208	+13%	+$11.9K	﹤0.01%	4653
2021 Q4	$111K	Hold	1,616	–	–	﹤0.01%	4557
2021 Q3	$256K	Hold	1,616	–	–	﹤0.01%	4261
2021 Q2	$315K	Sell	1,616 -7,612	-82%	-$1.91M	﹤0.01%	4032
2021 Q1	$2.38M	Sell	9,228 -4,436	-32%	-$1.17M	﹤0.01%	3367
2020 Q4	$2.64M	Sell	13,664 -439	-3%	-$86.2K	﹤0.01%	3252
2020 Q3	$2.86M	Buy	14,103 +93	+0.7%	+$22.3K	﹤0.01%	3055
2020 Q2	$3.92M	Buy	14,010 +4,845	+53%	+$1.33M	﹤0.01%	2884
2020 Q1	$2.75M	Buy	9,165 +3,343	+57%	+$949K	﹤0.01%	2918
2019 Q4	$1.87M	Buy	5,822 +1,088	+23%	+$390K	﹤0.01%	3274
2019 Q3	$1.8M	Buy	4,734 +2,036	+75%	+$806K	﹤0.01%	3251
2019 Q2	$1.21M	Buy	2,698 +2,108	+357%	+$1.07M	﹤0.01%	3387
2019 Q1	$308K	Sell	590 -5	-0.8%	-$2.76K	﹤0.01%	3520
2018 Q4	$248K	Sell	595 -113	-16%	-$43.1K	﹤0.01%	3540
2018 Q3	$205K	Buy	708 +343	+94%	+$145K	﹤0.01%	3601
2018 Q2	$239K	Buy	365 +52	+17%	+$170K	﹤0.01%	3548
2018 Q1	$1.29M	Buy	+313	New	+$911K	﹤0.01%	3300

Other funds holding XFOR

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street's XFOR Position: Q1 2026 in Review

State Street increased its X4 Pharmaceuticals (XFOR) stake by 104% in Q1 2026, buying an estimated $769K and bringing the position to 403,534 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #3349.

State Street first reported a position in XFOR in Q1 2018 and has held it in 33 quarters since. The position peaked at $4.31M in Q2 2023. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

State Street held 403,534 shares of X4 Pharmaceuticals worth $1.67M as of Q1 2026.
State Street bought 205,300 X4 Pharmaceuticals shares in Q1 2026, an estimated $769K.
X4 Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3349 holding.
State Street first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 33 quarters since.
State Street's X4 Pharmaceuticals position peaked at $4.31M in Q2 2023.
84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.